RxDoctor Payments Data

R Michael Tucker, MD

Family Medicine · Lehigh Acres, FLNPI 1497742936

Payments from drug & device makers

$9,830in general payments, 2019–2025

Across 535 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$945
  • Amgen$854
  • Lilly USA, LLC$823
  • Novo Nordisk$693
  • Novartis$638
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,830 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$278,623
Medicare patients
369
Services billed
7,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$156,005
EliquisApixaban105$83,153
MounjaroTirzepatide55$57,573
JardianceEmpagliflozin50$54,674
JanuviaSitagliptin Phosphate86$48,170
XareltoRivaroxaban72$35,521
VraylarCariprazine Hcl18$30,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,960
MyrbetriqMirabegron58$28,058
Repatha SureclickEvolocumab23$21,670
LinzessLinaclotide18$12,069
Breo ElliptaFluticasone/Vilanterol11$11,173
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$8,207
Spiriva RespimatTiotropium Bromide14$7,596
Humalog Kwikpen U-100Insulin Lispro24$7,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$693$156,005119 claims
PfizerEliquis$388$83,153105 claims
Boehringer IngelheimJardiance, Spiriva Respimat$40$62,27064 claims
Lilly USA, LLCMounjaro$823$57,57355 claims
MerckJanuvia, Dulera$162$51,14597 claims
AbbVieVraylar, Linzess$945$42,22436 claims
GSKTrelegy Ellipta, Breo Ellipta$1,396$41,13349 claims
Johnson & JohnsonXarelto$408$35,52172 claims
Astellas Pharma US IncMyrbetriq$324$28,05858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →